Regulation of eIF2α by RNF4 Promotes Melanoma Tumorigenesis and Therapy Resistance

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Melanoma is characterized by proteostasis defects and acquired resistance to targeted therapies, posing significant clinical challenges.
• The molecular mechanisms linking these hallmarks remain largely unknown.

Purpose of the Study:

• To elucidate the molecular machinery connecting proteostasis, tumorigenesis, and targeted therapy resistance in melanoma.
• To investigate the role of the ubiquitin ligase RNF4 in melanoma progression and drug resistance.

Main Methods:

• Utilized melanoma cell lines, xenograft mouse models, and patient samples to assess RNF4 function.
• Investigated the interaction between RNF4 and the translation initiation factor eIF2α using biochemical assays.
• Quantified RNF4 and phosphorylated eIF2α (p-eIF2α) levels in patient tumors and correlated them with clinical outcomes.

Main Results:

• RNF4 stabilizes key melanoma oncoproteins, promoting tumorigenesis and conferring resistance to targeted therapy.
• Elevated RNF4 levels in patients correlate with poor prognosis and resistance to MAPK inhibitors.
• RNF4-mediated therapy resistance is dependent on the translation initiation factor eIF2α, specifically its phosphorylated form (p-eIF2α).
• RNF4 directly binds, ubiquitinates, and stabilizes p-eIF2α, independent of ATF4 or CHOP.

Conclusions:

• RNF4 is a critical mediator of melanoma tumorigenesis and targeted therapy resistance.
• A positive feedback loop exists between RNF4 and p-eIF2α, linking oncogenic translation and protein stabilization in melanoma.
• Targeting RNF4 or the p-eIF2α pathway may represent a novel therapeutic strategy for melanoma.